• 1. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 2. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 3. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 4. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 5. Enantiocontrolled construction of sistodiolynne, an unusual polyketide from the wood-decay fungus Sistrema raduloides
  Chem. Commun., 1997, 767-768

Recent Advances in the Study of 4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(trifluoromethyl)benzenamine (CAS: 1259285-61-4)

The compound 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(trifluoromethyl)benzenamine (CAS: 1259285-61-4) has recently garnered significant attention in the field of chemical biology and medicinal chemistry. This boronic acid derivative is a key intermediate in the synthesis of various biologically active molecules, particularly in the development of kinase inhibitors and other targeted therapies. Its unique structural features, including the boronate ester moiety and the trifluoromethyl group, make it a versatile building block for drug discovery and development.

Recent studies have focused on the application of this compound in Suzuki-Miyaura cross-coupling reactions, a widely used method for forming carbon-carbon bonds in pharmaceutical synthesis. Researchers have demonstrated its utility in the efficient synthesis of complex molecules, such as tyrosine kinase inhibitors, which are critical in the treatment of cancers and inflammatory diseases. The trifluoromethyl group enhances the metabolic stability and bioavailability of the resulting compounds, making them more effective as therapeutic agents.

In addition to its synthetic applications, 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(trifluoromethyl)benzenamine has been investigated for its potential as a direct bioactive molecule. Preliminary studies suggest that it may exhibit inhibitory activity against certain enzymes involved in disease pathways, although further validation is required. The compound's mechanism of action and its interactions with biological targets are currently under rigorous investigation, with promising results that could lead to new therapeutic avenues.

Another area of interest is the compound's role in the development of boron neutron capture therapy (BNCT), an emerging treatment for aggressive cancers. The boron atom in the molecule can capture thermal neutrons, leading to localized radiation that targets cancer cells while sparing healthy tissue. This application highlights the compound's potential beyond traditional small-molecule drug development, positioning it as a multifunctional agent in both chemical and biomedical research.

Despite its promising applications, challenges remain in the large-scale synthesis and purification of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(trifluoromethyl)benzenamine. Recent advancements in catalytic systems and reaction optimization have improved yields and reduced byproducts, but further refinements are needed to meet industrial standards. Researchers are also exploring greener synthetic routes to minimize environmental impact, aligning with the growing emphasis on sustainable chemistry in drug development.

In conclusion, 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(trifluoromethyl)benzenamine (CAS: 1259285-61-4) represents a valuable tool in modern medicinal chemistry. Its diverse applications in synthesis, drug discovery, and innovative therapies underscore its importance in the field. Ongoing research will likely uncover additional uses and optimize its production, solidifying its role in the development of next-generation pharmaceuticals.

• 882679-08-5(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4-(trifluoromethyl)aniline)
• 1073353-65-7(2-(2,4-Bis(trifluoromethyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane)
• 1196972-92-5(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5-(trifluoromethyl)aniline)
• 676479-58-6(Siloxanes andSilicones, C>10-alkyl Me, di-Me, Me Pr)
• 1268693-25-9(2-(2,6-bis(trifluoromethyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane)
• 510771-54-7(3-Amino-5-trifluoromethylphenylboronic acid, pinacol ester)
• 1030832-71-3(2-Methyl-5-trifluoromethylphenylboronic Acid Pinacol Ester)
• 1073339-09-9(2-[2,5-bis(trifluoromethyl)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane)
• 879275-72-6(2-2-(Difluoromethyl)phenyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane)
• 1073339-21-5(4,4,5,5-Tetramethyl-2-(2-(trifluoromethyl)phenyl)-1,3,2-dioxaborolane)